Anti- PD-L1 (clone QR001)

PD-L1 (CD274, B7-H1) – A Key Marker for Immunotherapy
NordicQC Run C2 & C3 2018 Evaluation ✅ Optimal staining for clone QR001!
The Role of PD-L1 in Immune Regulation
✔ PD-L1 (CD274, B7-H1) is a protein that inhibits T-cell activation and immune response by binding to the PD-1 receptor on cytotoxic T lymphocytes.
✔ Many tumors upregulate PD-L1 expression, leading to T-cell inactivation and allowing the tumor to evade immune surveillance.
✔ Anti-PD-1/PD-L1 therapy restores immune function by blocking this inhibitory pathway, allowing T cells to target and destroy tumor cells.
Clinical Significance of PD-L1 in Cancer
✔ PD-L1 expression assessment in tumor cells helps identify patients who may benefit from PD-1/PD-L1 inhibitor therapy.
✔ PD-L1 is expressed in multiple tumor types, including:
  
Non-small cell lung cancer (NSCLC)
  
Malignant melanoma
  
Renal cell carcinoma (RCC)
  
Bladder cancer
  
Gastric cancer
  
Colorectal cancer (CRC)
  
Pancreatic cancer
  
Triple-negative breast cancer (TNBC)
  
Classical Hodgkin lymphoma (CHL)
  
Other malignancies
Anti-PD-L1 (QR001) Antibody – High Sensitivity and Specificity
✔ The rabbit monoclonal anti-PD-L1 antibody (QR001) provides:
  
Consistent performance
  
No cross-reactivity with PD-L2 or other antigens
  
High specificity and sensitivity, validated in international studies and quality assurance programs
✔ Laboratory-developed assays (LDA) using QR001 for PD-L1 status assessment:
  
Reduce costs by up to 5-fold compared to commercial diagnostic tests
  
Maintain high-quality results
Summary
✔ PD-L1 is a key predictive marker for cancer immunotherapy.
✔ Its expression is found in multiple cancers, including NSCLC, melanoma, RCC, and TNBC.
✔ QR001 ensures high-quality staining with no PD-L2 cross-reactivity.
✔ IHC-based PD-L1 evaluation enables better patient selection for anti-PD-1/PD-L1 therapy, potentially improving treatment outcomes.